Skip to content

Bruker BRKR Fair value of long-term debt

Fair value of long-term debt at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$823.4M+2.7%
Gross profit$379.8M-2.9%
Operating income$10.2M-67.9%
Net income$14.4M-17.2%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$137.6M-26.7%
Total debt$1.7B-20.9%
Total equity$2.5B+34.6%
Total assets$6.1B+3.3%

Cash flow

See full
Operating cash flow$71.2M+9.5%
CapEx$24.2M-6.9%
Free cash flow$47.0M+20.5%

Valuation

See full
Market cap$8.71B-13.2%
Enterprise value$10.25B-14.9%
P/S2.5×-0.4×

Profitability

See full
Gross margin45.3%-3.7pp
Operating margin1.3%-5.0pp
Net margin-0.6%-10.0pp
FCF margin1.5%-3.6pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.7×-0.5×
Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtFairValue.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's fair value of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bruker's fair value of long-term debt?
Bruker (BRKR) reported fair value of long-term debt of $1.41B in Q1 2026.
How has Bruker's fair value of long-term debt changed year-over-year?
Bruker's fair value of long-term debt increased by 9.2% year-over-year, from $1.29B to $1.41B.
What is the long-term trend for Bruker's fair value of long-term debt?
Over 3 years (2022 to 2025), Bruker's fair value of long-term debt has grown at a 23.1% compound annual growth rate (CAGR), from $767.8M to $1.43B.